Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.

Inclusion Criteria: * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age greater than or equal to 50 years * Best-corrected ETDRS VA between 20/25 to 20/320 * Total area of subretinal hemorrhage and/or fibrosis comprising less than 50% of lesion * Any neovascular lesion type of ARMD having previously received at least 3 doses 1.25 mg of bevacizumab and/or ranibizumab (minimum 3 monthly injections) followed by 3 monthly doses of aflibercept 2.0 mg (with last injection being within 8 weeks) with evidence of recalcitrant ARMD, defined by at least one of the following: persistent subretinal fluid with or without intraretinal cystic edema on SD-OCT and/or leakage on fluorescein angiography Exclusion Criteria: * Pregnancy (positive pregnancy test) or lactation or pre-menopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch * Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated * Participation in another simultaneous medical investigation or trial * History of prior vitrectomy surgery * Previous treatment with photodynamic therapy, radiation, or any other intravitreal drug delivery, such as dexamethasone or triamcinolone * Subretinal hemorrhage involving the central fovea \> 1 disc area, subfoveal atrophy * CNVM secondary to causes other than ARMD * Previous retinal pigment epithelial tear